文献速递主动脉疾病

编辑精选——血管内动脉瘤修复术后II型内漏治疗结果的系统综述与Meta分析

Editor's Choice - Systematic Review and Meta-Analysis of the Outcome of Treatment for Type II Endoleak Following Endovascular Aneurysm Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-08-10

该系统综述与Meta分析纳入59项研究、1073例EVAR术后持续性II型内漏患者,评估不同治疗方式的结局。围手术期并发症发生率3.8%(95%CI 2.7-5.2%),AAA相关死亡率1.8%(95%CI 1.1-2.7%),总体技术成功率87.9%(95%CI 83.1-92.1%),临床成功率68.4%(95%CI 61.2-75.1%)。作者认为支持II型内漏二次干预有效性的证据很少。

要点

  • 围手术期并发症发生率3.8%(95%CI 2.7-5.2%),AAA相关死亡率1.8%(95%CI 1.1-2.7%)。
  • 总体技术成功率87.9%(95%CI 83.1-92.1%),临床成功率68.4%(95%CI 61.2-75.1%)。
  • 作者认为支持EVAR术后II型内漏二次干预有效性的证据很少。

核心结论

  • 支持EVAR术后II型内漏二次干预有效性的证据很少;虽总体安全,但缺乏有效性证据导致难以评估其价值。

研究设计与样本

  • 系统综述与Meta分析,检索Embase、Medline(via Ovid)、Web of Science Core Collection、Cochrane CENTRAL和Google Scholar,纳入59项研究、累计1073例EVAR术后持续性II型内漏患者,采用随机效应模型进行Meta分析。

主要发现

  • 治疗II型内漏后围手术期并发症发生率为3.8%(95%CI 2.7-5.2%),AAA相关死亡率为1.8%(95%CI 1.1-2.7%)。
  • 总体技术成功率为87.9%(95%CI 83.1-92.1%),临床成功率为68.4%(95%CI 61.2-75.1%)。
  • 在详细记录瘤囊动态的研究中,瘤囊缩小或稳定(伴或不伴内漏消失)的比例为78.4%(95%CI 70.2-85.6%)。
  • 157例患者记录了II型内漏治疗后至少24个月的瘤囊直径变化,该组中仅40例中的27例报告瘤囊直径实际缩小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The efficacy and need for secondary interventions for type II endoleaks following endovascular abdominal aortic aneurysm repair (EVAR) remain controversial. This systematic review aimed at investigating the clinical outcomes of different type II endoleak treatments in patients with a persistent type II endoleak after EVAR. DATA SOURCES: Embase, Medline via Ovid, Web of Science Core Collection, the Cochrane CENTRAL, and Google Scholar. REVIEW METHODS: This systematic review was performed in accordance with the PRISMA Statement. Outcomes of interest were technical and clinical success, change in sac diameter, complications, need for additional interventions, abdominal aortic aneurysm (AAA) rupture, and (AAA related) mortality. Meta-analyses were performed with random effects models. RESULTS: A total of 59 studies were included, with a cumulative cohort of 1073 patients with persistent type II endoleak. Peri-operative complications following treatment of type II endoleaks occurred in 3.8% of patients (95% CI 2.7-5.2%), and AAA related mortality was 1.8% (95% CI 1.1-2.7%). Overall technical success was 87.9% (95% CI 83.1-92.1%), while clinical success was 68.4% (95% CI 61.2-75.1%). Among studies detailing sac dynamics, decrease or stable sac, with or without resolution, was achieved in 78.4% (95% CI 70.2-85.6%). Changes in sac diameter following type II endoleak treatment were documented in 157 patients to at least 24 months. Within this group an actual decrease in sac diameter was reported in only 27 of 40 patients. CONCLUSION: There is little evidence supporting the efficacy of secondary intervention for type II endoleaks after EVAR. Although generally safe, the lack of evidence supporting the efficacy of type II endoleak treatment leads to difficulty in assessing its merits.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ultee KHJ, Büttner S, Huurman R, et al. Editor's Choice - Systematic Review and Meta-Analysis of the Outcome of Treatment for Type II Endoleak Following Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2018. PMID: 30104089. doi:10.1016/j.ejvs.2018.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。